story of the week
Yet Another Study Supporting Extended-Interval Ocrelizumab Dosing in Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis (Houndmills, Basingstoke, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity
Mult. Scler. 2023 Nov 09;[EPub Ahead of Print], N Bou Rjeily, KC Fitzgerald, EM MowryFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.